Market Overview:
The global trastuzumab biosimilar market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of breast cancer and gastric cancer, rising demand for cost-effective therapies, and growing preference for biosimilars over branded drugs. Based on type, the global trastuzumab biosimilar market can be segmented into adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others. Adjuvant breast cancer is expected to account for the largest share of the global trastuzumab biosimilar market in 2018 owing to high prevalence of this disease across regions. By application, hospital pharmacy accounted for the largest share of the global trastuzumab biosimilar market in 2017. However, online pharmacy is projected to grow at a higher CAGR during the forecast period from 2018 to 2030 due to increasing penetration of e-commerce platforms worldwide. Geographically, North America was estimated as having held majority share (XX%) in 2017 followed by Europe which accounted second highest revenue contribution (XX%). Asia Pacific region has been identified as fastest growing regional segment with XX% CAGR over next 10 years owing rapid adoption rate Trastuzmub Biosimilars coupled with presence major players manufacturing these products within region .
Product Definition:
Trastuzumab biosimilar is a protein therapeutic agent which is used for the treatment of cancer. It is a recombinant humanized monoclonal antibody that binds to and inhibits the activity of HER2, a protein found on the surface of some cancer cells. Trastuzumab biosimilar is important because it offers an alternative to the original trastuzumab product, which can be expensive and difficult to access in some parts of the world.
Adjuvant Breast Cancer:
Adjuvant breast cancer is a type of breast cancer that develops in women who have been through radiation therapy for early-stage disease. The presence of the BRCA1 and BRCA2 genes may increase the risk of developing this form of cancer.
Metastatic Breast Cancer:
Metastatic breast cancer is a type of breast cancer that has spread to other organs or tissues in the body. It can occur in one or both breasts, and it's usually found when a person is between 50 and 60 years of age. There are two types of metastatic breast cancers: non-palpable (infiltrating) and palpable (non-infiltrating).
Application Insights:
Based on the application, the global market is segmented into hospital pharmacy and online pharmacy. The hospital pharmacy segment dominated the overall industry in terms of revenue in 2017 owing to increasing demand for trastuzumab biosimilars across various applications such as adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer and others.
The online pharma-cycling business is expected to witness lucrative growth over the forecast period due to growing awareness about affordable healthcare coupled with rising incidences of chronic diseases such as diabetes which drives people towards medication. According to a study published by NCBI in 2018, it was estimated that around 1/3rd of adults suffer from some form of mental illness while 1/4th are living with some kind of disability worldwide. Growing prevalence rates coupled with rising awareness about available treatment options are anticipated fuel demand for medication globally over the forecast period thereby driving growth for this segment during future years.
Regional Analysis:
North America dominated the global trastuzumab biosimilar market in 2016 with a revenue share of over 50%. This is attributed to the presence of key players, high adoption rate for biosimilars, and increasing healthcare expenditure. In addition, approval of first-line trastuzumab biosimilar in U.S. is expected to boost regional growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative CAGR during the forecast period due its large population base.
Growth Factors:
- Increasing incidence of breast cancer: The incidence of breast cancer is increasing at a rapid pace across the globe. This is expected to drive the demand for trastuzumab biosimilars in the coming years.
- Growing awareness about trastuzumab biosimilars: There is a growing awareness among patients and healthcare professionals about the benefits of trastuzumab biosimilars. This is likely to boost the demand for these drugs in the coming years.
- Availability of affordable trastuzumab biosimilars: Trastuzumab biosimilars are available at a fraction of the cost of branded versions, making them an attractive option for patients and healthcare providers alike. This is likely to fuel their adoption in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Trastuzumab Biosimilar Market Research Report
By Type
Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Others
By Application
Hospital Pharmacy, Online Pharmacy
By Companies
Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Teva Pharmaceutical, Genentech, Mundipharma, Celltrion, Henlius
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
183
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Trastuzumab Biosimilar Market Report Segments:
The global Trastuzumab Biosimilar market is segmented on the basis of:
Types
Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Online Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc.
- Pfizer Inc
- Samsung Bioepis
- Merck & Co.
- Biocon Limited
- Teva Pharmaceutical
- Genentech
- Mundipharma
- Celltrion
- Henlius
Highlights of The Trastuzumab Biosimilar Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Adjuvant Breast Cancer
- Metastatic Breast Cancer
- Metastatic Gastric Cancer
- Others
- By Application:
- Hospital Pharmacy
- Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Trastuzumab Biosimilar Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tramustine biosimilar is a type of medication that is similar to the cancer drug tramustine. Trastuzumab biosimilar is intended to replace the original tramustine in treating certain types of cancer.
Some of the key players operating in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Teva Pharmaceutical, Genentech, Mundipharma, Celltrion, Henlius.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Trastuzumab Biosimilar Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Trastuzumab Biosimilar Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Trastuzumab Biosimilar Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Trastuzumab Biosimilar Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Trastuzumab Biosimilar Market Size & Forecast, 2020-2028
4.5.1 Trastuzumab Biosimilar Market Size and Y-o-Y Growth
4.5.2 Trastuzumab Biosimilar Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Adjuvant Breast Cancer
5.2.2 Metastatic Breast Cancer
5.2.3 Metastatic Gastric Cancer
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Online Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Trastuzumab Biosimilar Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Trastuzumab Biosimilar Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Adjuvant Breast Cancer
9.6.2 Metastatic Breast Cancer
9.6.3 Metastatic Gastric Cancer
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Online Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Adjuvant Breast Cancer
10.6.2 Metastatic Breast Cancer
10.6.3 Metastatic Gastric Cancer
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Online Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Adjuvant Breast Cancer
11.6.2 Metastatic Breast Cancer
11.6.3 Metastatic Gastric Cancer
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Online Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Adjuvant Breast Cancer
12.6.2 Metastatic Breast Cancer
12.6.3 Metastatic Gastric Cancer
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Online Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Adjuvant Breast Cancer
13.6.2 Metastatic Breast Cancer
13.6.3 Metastatic Gastric Cancer
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Online Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Trastuzumab Biosimilar Market: Competitive Dashboard
14.2 Global Trastuzumab Biosimilar Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen Inc.
14.3.2 Pfizer Inc
14.3.3 Samsung Bioepis
14.3.4 Merck & Co.
14.3.5 Biocon Limited
14.3.6 Teva Pharmaceutical
14.3.7 Genentech
14.3.8 Mundipharma
14.3.9 Celltrion
14.3.10 Henlius
